DSM-Firmenich's FY 2024 results show promising growth and profitability, with 6% organic sales growth and 19% adjusted EBITDA increase, despite a challenging macroeconomic environment. The company is making progress on the promised synergies, targeting €350 million in total run-rate synergies by 2028. DSM-Firmenich's innovation capabilities, supported by over 2,000 R&D scientists and 16,000 patents, are driving new product launches and revenue synergies.
Dimitri De Vreeze, CEO of Dsm-Firmenich, talks about the company's merger and share buyback program off the back of its full-year earning results.
DSM-Firmenich AG (OTC:KDSKF) Q2 2024 Earnings Conference Call July 30, 2024 3:00 AM ET Company Participants Dave Huizing - Head of Investor Relations Dimitri de Vreeze - Chief Executive Officer Ralf Schmeitz - Chief Financial Officer Conference Call Participants Charles Eden - UBS Nicola Tang - BNP Paribas Artem Chubarov - Redburn Atlantic Isha Sharma - Stifel Chetan Udeshi - JPMorgan Georgina Fraser - Goldman Sachs Alex Sloane - Barclays Matthew Yates - Bank of America Fernand de Boer - DeGroof Petercam Dave Huizing Good morning and thank you for joining today's call. I'm sitting here with Dimitri de Vreeze, our CEO; and Ralf Schmeitz, our CFO.
Dublin, June 05, 2024 (GLOBE NEWSWIRE) -- The "Ruminant Methane Reduction Market Size, Share & Trends Analysis Report By Product (Feed Additives/ Supplements (Plant-based, Chemical-based, Microbial-based)), By Animal Type (Cattle, Sheep, Goats), By Region, And Segment Forecasts, 2024 - 2030" report has been added to ResearchAndMarkets.com's offering. The global ruminant methane reduction market size is anticipated to reach USD 3.98 billion by 2030, growing at a CAGR of 7.03% during the forecast period.